Equities Analysts Offer Predictions for CryoPort Q2 Earnings

CryoPort, Inc. (NASDAQ:CYRX) – Equities researchers at Leerink Partnrs increased their Q2 2025 earnings per share (EPS) estimates for shares of CryoPort in a research note issued to investors on Thursday, July 17th. Leerink Partnrs analyst P. Souda now anticipates that the company will earn ($0.19) per share for the quarter, up from their prior forecast of ($0.21). The consensus estimate for CryoPort’s current full-year earnings is ($0.99) per share. Leerink Partnrs also issued estimates for CryoPort’s Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.79) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.14) EPS and FY2026 earnings at ($0.68) EPS.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. The company had revenue of $41.04 million for the quarter, compared to the consensus estimate of $56.19 million. CryoPort had a negative return on equity of 11.03% and a negative net margin of 50.15%.

A number of other research firms also recently weighed in on CYRX. UBS Group increased their price target on CryoPort from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, April 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of CryoPort in a research note on Thursday, May 8th. Morgan Stanley dropped their price objective on CryoPort from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Monday, May 5th. BTIG Research dropped their price objective on CryoPort from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, July 7th. Finally, Roth Mkm reaffirmed a “buy” rating and set a $15.00 price objective on shares of CryoPort in a research note on Tuesday, April 1st. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, CryoPort has a consensus rating of “Moderate Buy” and a consensus price target of $10.88.

CryoPort Stock Performance

CYRX stock opened at $7.19 on Monday. The business’s fifty day moving average is $6.84 and its 200-day moving average is $6.63. The company has a quick ratio of 5.24, a current ratio of 5.56 and a debt-to-equity ratio of 0.51. The company has a market cap of $360.51 million, a P/E ratio of -3.07 and a beta of 1.89. CryoPort has a twelve month low of $4.58 and a twelve month high of $9.78.

Insider Transactions at CryoPort

In other CryoPort news, insider Edward J. Zecchini sold 51,500 shares of CryoPort stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $6.84, for a total value of $352,260.00. Following the sale, the insider owned 90,411 shares of the company’s stock, valued at $618,411.24. This trade represents a 36.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ramkumar Mandalam sold 13,321 shares of the firm’s stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $7.01, for a total value of $93,380.21. Following the completion of the transaction, the director owned 73,056 shares of the company’s stock, valued at $512,122.56. The trade was a 15.42% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 449,719 shares of company stock worth $3,042,327. Company insiders own 10.10% of the company’s stock.

Hedge Funds Weigh In On CryoPort

Several hedge funds have recently modified their holdings of the stock. Avanza Fonder AB grew its holdings in shares of CryoPort by 31.4% in the 2nd quarter. Avanza Fonder AB now owns 10,882 shares of the company’s stock valued at $81,000 after acquiring an additional 2,601 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in CryoPort by 7.3% during the second quarter. Assenagon Asset Management S.A. now owns 1,090,511 shares of the company’s stock worth $8,135,000 after purchasing an additional 73,949 shares during the period. Wealth Enhancement Advisory Services LLC bought a new position in CryoPort during the second quarter worth about $123,000. Rhumbline Advisers grew its holdings in CryoPort by 23.8% during the first quarter. Rhumbline Advisers now owns 78,320 shares of the company’s stock worth $476,000 after purchasing an additional 15,036 shares during the period. Finally, Acadian Asset Management LLC grew its holdings in CryoPort by 106.4% during the first quarter. Acadian Asset Management LLC now owns 479,695 shares of the company’s stock worth $2,911,000 after purchasing an additional 247,288 shares during the period. Institutional investors own 92.90% of the company’s stock.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.